NurExone Secures over C$3.18 Million Through Accelerated Warrant Exercises

NurExone Honored at Berlin and Stockholm Conferences for Breakthrough Contributions to Global Life Sciences and Health Innovation

TORONTO and HAIFA, Israel, Nov. 12, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is pleased to announce that, further to its press release dated October 8, 2025 (the “October 8 Release”), the Company has received gross proceeds of over C$3.18M through accelerated warrant exercises.

The breakdown of the proceeds is as follows: (i) C$1,207,418.88 through the exercise of 2,515,456 September 2023 Warrants at a price of C$0.48 per September 2023 Warrant issued from a non-brokered private placement which closed in tranches on August 25, 2023 and September 6, 2023 and (ii) C$1,978,575.55 through the exercise of 5,653,073 January 2024 Warrants at a price of C$0.35 per January 2024 Warrant issued from a non-brokered private placement which closed on January 4, 2024. Capitalized terms not otherwise defined herein have the meanings attributed to them in the October 8 Release.

Following the Company providing the outstanding holders of the September 2023 Warrants and January 2024 Warrants acceleration notices on October 8, 2025 notifying them that their acceleration triggers were met, when the daily volume average trading price of the Common Shares on the TSXV equaled or exceeded C$0.83, in the case of the September 2023 Warrants, and C$0.80, in the case of the January 2024 Warrants, for a period of 20 consecutive trading days, all of the September 2023 Warrants and January 2024 Warrants were exercised their warrants prior to expiry, providing the Company an aggregate of C$3,185,994.43 in gross proceeds.

The proceeds from these exercises strengthen NurExone’s balance sheet and will be used for general corporate purposes and working capital, supporting ongoing development of Company’s exosome-based therapeutic platform.

Management Commentary

“We are very pleased with the full participation from warrantholders during the accelerated exercise period,” said Dr. Lior Shaltiel, Chief Executive Officer of NurExone. “This additional capital enhances our financial strengths as we continue advancing ExoPTEN and our therapeutic pipeline towards clinical readiness.”

Eran Ovadya, Chief Financial Officer of NurExone, added: “The full participation of these warrantholders reflects investor confidence in NurExone’s strategy and our exosome-based platform. The resulting funds provide further financial stability, enabling us to efficiently allocate resources towards clinical development and key operational priorities, while maintaining a strong balance sheet.”